Underutilization of ACE inhibitors in heart failure

Pharmacotherapy

Volumn 19, Issue 11 I, 1999, Pages 1296-1307

  Luzier, Aileen Bown ^a   DiTusa, Lisanne ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NITRATE; QUINAPRIL; RAMIPRIL;

AMBULATORY CARE; COMMUNITY HOSPITAL; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; DRUG UTILIZATION; GERIATRIC CARE; HEALTH CARE COST; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HUMAN; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032742861     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.16.1296.30880     Document Type: Review

References (63)

1. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22(suppl A):3A-5.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73.
3. Vince JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990;38:1290-5.
4. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
5. Naylor M, Brooten D, Jones R, Lavixxo-Mourey R, Mezey M, Pauly M. Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial. Ann Intern Med 1994;120:999-1006.
6. Philbin EF. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med 1999;14(2):130-5.
7. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical practice guideline 11. Rockville, MD: Agency for Health Care Policy and Research, 1994.
8. American College of Cardiology/American Heart Association Task Force. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee for the evaluation and management of heart failure). Circulation 1995;92(9):2764-84.
9. European Society of Cardiology. Treatment of heart failure, report of the task force of the working group on heart failure of the European Society of Cardiology. Eur Heart J 1997;18(5):736-53.
10. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
12. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
13. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
14. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
15. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:832-8.
16. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
17. Deedwania PC. Underutilization of evidence-based therapy in heart failure. An opportunity to deal a winning hand with an ACE up your sleeve. Arch Intern Med 1997;157:2409-12
18. Croft JB, Giles WH, Roegner RH, Adna RF, Casper ML, Livengood JR. Pharmacologic management of heart failure among older adults by office-based physicians in the United States. J Fam Pract 1997;44:382-90.
19. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
20. McDermott MM, Lee P, Mehta S, Gheorghiade M. Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. Clin Cardiol 1998;21(4):261-8.
21. Clinical Quality Improvement Network (CQIN) Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Arch Intern Med 1996;156:1669-73.
22. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997;157:2460-4.
23. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994;71:584-7.
24. Philbin EF. Factors determining angiotensin-converting enzyme underutilization in heart failure in a community setting. Clin Cardiol 1998;21(2):103-8.
25. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Izzo JL. Impact of angiotensin-converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
26. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997;30:733-8.
27. Smith NL, Psaty BM, Pitt B, Garg R, Gottdiener JS, Heckbert SR. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998;158(10):1074-80.
28. Mendelson G, Aronow WS. Underutilization of angiotensin-converting enzyme inhibitors in older patients with Q-wave anterior myocardial infarction in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1998;46(6):751-2.
29. Hood S, Taylor S, Hemingway H. Older patients and advances in cardiology. Lancet 1997;350(9093):1779-80.
30. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997;134:188-95.
31. Young JB, Weiner DH, Yusuf S, et al. Patterns of medication use in patients with heart failure: a report from the registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J 1995;88(5):514-23.
32. Chin MH, Wang JC, Zhang JX, Lang RM. Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristics. J Gen Intern Med 1997;12(9):563-6.
33. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the Unites States: data from the National Registry of Myocardial Infarction 2. J Am Coll Cardiol 1998;32:360-7.
34. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health 1997;87(4):643-8.
35. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997;157:1103-8.
36. Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997;157:2242-7.
37. O'Connell JB, Cobb AB, and the Heart Failure Study Group. Heart failure evaluation and treatment in Mississippi: results from a survey of the Mississippi Foundation for Medical Care. J Miss State Med Assoc 1996;37(7):648-52.
38. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥ 65 years of age. Am J Cardiol 1997;79:581-6.
39. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79(8):1118-20.
40. Luzier AB, Navsarikar A, Wilson M, Ashai K, Forrest A. Patterns of prescribing ACE inhibitors after myocardial infarction. Pharmacotherapy 1999;19(5):655-60.
41. Cleland JGF, Poole-Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J 1994;72(3 suppl): S106-10.
42. Cleland JGF. ACE inhibitors in heart failure. What dose? Postgrad Med J 1995;71:65-6.
43. Packer M, Poole-Wilson P, Armstrong P, et al. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival Study (ATLAS) [abstr]. Eur Heart J 1998;19(suppl):142.
44. Luzier AB, Feuerstein SG, Schentag JJ, Izzo JL. Impact of clinical pharmacist-based intervention on outcomes in congestive heart failure [abstr], Pharmacotherapy 1999; 19(4):478.
45. Gattis WA, Larsen RL, Hasselblad V, Bart BA, O'Connor CM. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? Am Heart J 1998;136:43-8.
46. Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose ACE inhibition in chronic heart failure, a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998;32:1811-18.
47. Houghton AR, Cowley AJ. Why are angiotensin-converting enzyme inhibitors underutilized in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59(1):7-10.
48. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
49. McMurray JJV. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998;19(suppl L):L15-21.
50. Cleland JGF. ACE inhibitors for the prevention and treatment of heart failure: why are they "under-used"? J Hum Hypertens 1995;94:35-42.
51. Sheiner MA, Kimmel SE. Heart failure and angiotensin-converting enzyme inhibitors. Is there a need for specialty care? J Gen Intern Med 1997;12(9):581-2.
52. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993;22:198A-200.
53. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalists' and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997;12(9):523-30.
54. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice. J Am Coll Cardiol 1996;28(5): 1323-7.
55. Ljungman S, Kjekshus J, Swedberg K, et al. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS]). Am J Cardiol 1992;70:479-87.
56. Mirvis DM, Insel J, Boland MJ. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-54.
57. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
58. Struthers AD. Identification, diagnosis and treatment of heart failure: could we do better? Cardiology 1996;87(suppl 1):29-32.
59. American Society for Hospital Pharmacists. Therapeutic guidelines on angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction. Am J Health-Syst Pharm 1997;54:299-313.
60. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure. JAMA 1994;272:1361-6.
61. The Consensus Trial Study Group. Tolerability of enalapril in congestive heart failure. The Cooperative North Scandinavian Enalapril Study group (CONSENSUS). Am J Cardiol 1988;62(suppl A):67A-72.
62. Hood WB, Youngblood M, Ghali JK, et al. Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1991;68:1465-8.
63. Schwartz D, Averbuch M, Pines A, Kornowski R, Yoram L. Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure. Chest 1991;100:1558-61.